U.K. Government Grant Unlocks £33M Investment With Kindeva Drug Delivery for Greener Inhaler Future
Kindeva Drug Delivery (Kindeva), a premier global drug delivery device contract development and manufacturing organization (CDMO), announced that the company has received a grant from the U.K. Government’s Life Sciences Innovation Manufacturing Fund (LSIMF), unlocking a £33 million investment with Kindeva toward enhancing inhaler manufacturing and sustainability. The joint funds enhance Kindeva’s capability and capacity to manufacture the next generation of green pressurized metered-dose inhalers (pMDIs) and to continue delivering ever-evolving therapies for respiratory diseases worldwide.
“This joint investment of public and private funds creates myriad new opportunities for Kindeva colleagues within the U.K., as significant technical and regulatory expertise is required in the development and manufacturing of complex inhalation products,” said Kindeva Global Chief Commercial Officer David Stevens. “This investment provides Kindeva with a springboard to expand our capabilities and capacity, while simultaneously partnering with leading pharmaceutical companies around the world to bring the next generation of green inhalers to market — with a common goal of safeguarding access to necessary therapies for patients and reducing our impact on the planet.”
This investment supports global development and manufacturing of inhalers using new, lower global warming potential (GWP) propellants, while creating and safeguarding local jobs across the company’s two U.K. sites — Loughborough and Clitheroe. Additionally, this industry and government investment supports:
- New manufacturing capability and capacity in Loughborough for the next generation of green inhalers
- Green improvements to Kindeva’s underlying inhaler componentry supply chain at the company’s Clitheroe site
- Pharmaceutical companies as they make green transitions with existing products —reducing GWP emissions and helping meet sustainability targets — as well as the opportunity to bring new green inhalers and respiratory therapies to patients
The U.K. grant is the sixth investment through the LSIMF, which has supported U.K. life sciences manufacturing with £340 million in joint government and industry backing in the last financial year.
About Kindeva Drug Delivery
Kindeva is a global contract development manufacturing organization focused on drug-device combination products. Kindeva develops and manufactures products across a broad range of complex drug-delivery formats, including injectables (autoinjector, intradermal, microneedle), pulmonary & nasal, and transdermal patches. Its service offering spans early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from its nine manufacturing and research and development facilities located in the U.S. and U.K.
For more information, please visit www.kindevadd.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Esri Launches Online GIS Course for Climate Action28.9.2023 23:01:00 EEST | Press release
As the impacts of climate change increase and intensify around the world, one aspect that has become clear is the geographic nature of the issue. The ability to tackle such a wide-reaching geographic challenge requires technology that gives context, which location intelligence provides. To support the individuals working toward this goal, Esri, the global leader in geographic information system (GIS) technology, today announced it will offer a new massive open online course (MOOC) exploring the application of its software to address climate change impacts. The complimentary course will be available this fall for six weeks on the Esri Academy website and includes full access to ArcGIS Pro, ArcGIS Network Analyst, ArcGIS Online, and other ArcGIS software that uses science-based tools and authoritative data. GIS for Climate Action opens on October 25 and provides a comprehensive introduction to how GIS software is used to ingest, map, visualize, analyze, and share massive amounts of data.
Bartek Ingredients on Track with New Facility Doubling Capacity and Cutting Emissions by 80 Percent28.9.2023 22:43:00 EEST | Press release
Bartek Ingredients is pleased to provide an update on its progress on the world’s largest malic and fumaric acid manufacturing facility. The project, which broke ground in January 2023, is on schedule to deliver product to customers by the end of September 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230928870100/en/ New Bartek manufacturing facility on track to deliver product by September 2024. (Photo: Business Wire) “We’re proud to confirm that we’re progressing as expected,” Bartek CEO John Burrows said. “We’re really excited to deliver our expanded capacity by next summer, in addition to new capabilities for a variety of new products.” Bartek expects the new facility to set a new global benchmark for plant safety, efficiency, and environmental performance. Among its anticipated accomplishments is a doubling of Bartek’s production capacity and a per unit greenhouse gas emissions reduction of more than 80 percent.
Brenus Pharma unveils promising pre-clinical results extrapolating human conditions in major international congresses.28.9.2023 17:30:00 EEST | Press release
Brenus Pharma announces that pre-clinical advancements of its inaugural research program were presented at the 7th CICON (International Cancer Immunotherapy) Conference in Milan, Italy (September 20-23) and will be showcased at the 38th Annual SITC (Society for Immunotherapy of Cancer) Congress in San Diego, CA, USA (November 1-5) These communications focus on pre-clinical validation of new developments of the first product generated by the STC Platform, STC-1010, which targets colorectal cancer in a first line of treatment. CONFERENCE TITLE AUTHORS RESULTS CICON23 P119: Allogenic Tumor Cell-Based Vaccine to Treat Colorectal Cancer: Development and Preclinical Validation George ALZEEB, Scientific Project Manager, Brenus Pharma, (Ph.D) Corinne TORTORELLI, Medical Lead, Brenus Pharma, (Pharm. D., Ph.D) Corentin RICHARD, Postdoc, Centre Georges-François Leclerc, ICMUB UMR CNRS 6302, (PhD) Romain BOIDOT, Molecular biologist, Centre Georges-François Leclerc, ICMUB UMR CNRS 6302, (PhD) Tangu
BM3EAC Corp. 2023 Semi-Annual Report28.9.2023 16:15:00 EEST | Press release
BM3EAC Corp. (the “Company”), a special purpose acquisition company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., today published its semi-annual report for the period 1 January 2023 to 30 June 2023. The semi-annual report can be downloaded from the Company’s website via the following link: https://www.BrigadeM3EAC.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announ
ASM Global and Leading Finnish Development Company Suvilahden Areena Oy to Partner in Major Helsinki Entertainment Venue Exploration28.9.2023 16:00:00 EEST | Press release
ASM Global, the world’s largest producer of entertainment experiences, and Suvilahden Areena Oy have announced an unprecedented alliance to propose serving as the lead in the future reimagination of Helsinki’s sprawling iconic and historic Hanasaari power plant built in 1909. The duo’s aim is to preserve as much of the legendary landmark building while integrating local culture and environment in combination with a state-of-the-art arena and festival area within the development. ASM Global will anchor the music and live-entertainment venue while exploring incorporating sports programming on a major scale. ASM Global Europe President Chris Bray said, “Hanasaaren voimala is a major next step for ASM Global in Finland. We already have a strong presence in Scandinavia and are now building on our recent expansion into Helsinki, which includes Kulttuuritalo. We believe that with our unrivalled global network, we will bring the world’s most sought-after concerts and artists to fans in Helsink
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom